GMAX BIOPHARM
Gmax Biopharm dvelope innovative GPCR Antibody therapeutics for unmet medical use.
GMAX BIOPHARM
Social Links:
Industry:
Biotechnology Clinical Trials Health Care Product Research
Founded:
2010-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.gmaxbiopharm.com
Total Employee:
11+
Status:
Active
Contact:
86-571-866-33907
Email Addresses:
[email protected]
Total Funding:
78 M USD
Technology used in webpage:
SPF SSL By Default Nginx DigiCert SSL RapidSSL China Telecom Alibaba Cloud MailBox DNS Pod
Current Employees Featured
Founder
Investors List
Tigermed
Tigermed investment in Series C - Gmax Biopharm
Cowin Capital
Cowin Capital investment in Series C - Gmax Biopharm
China Merchants Group
China Merchants Group investment in Series C - Gmax Biopharm
Brill Capital
Brill Capital investment in Series C - Gmax Biopharm
Official Site Inspections
http://www.gmaxbiopharm.com Semrush global rank: 4.68 M Semrush visits lastest month: 2.08 K
Unable to get host informations!!!
More informations about "Gmax Biopharm"
GPCRs|GPCR mAb discovery platform|Monoclonal Antibody …
Gmax Biopharm International Limited is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and M-Body development, to …See details»
Gmax Biopharm LLC.--Gmax|Gmax Biopharm|Biopharm
Gmax has built up an in-house antibody development platform which enables the antibody screening, humanization, and engineering, in order to obtain the antibody candidates with …See details»
Gmax Biopharm - Crunchbase Company Profile & Funding
Also Known As gmaxbiopharm, Gmax Biopharm LLC., 鸿运华宁(杭州)生物医药有限公司; Legal Name Gmax Biopharm International Limited; Company Type For Profit; Contact Email …See details»
Overview - Gmax Biopharm
Gmax Biopharm International Limited is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and M-Body development, to …See details»
GMAX Bio Company Profile 2024: Valuation, Funding & Investors
GMAX Bio General Information Description. Provider and developer of new drugs designed for cardiovascular diseases, metabolic disorders and cancer. The company focuses on G-protein …See details»
Gmax Biopharm - PharmaBoardroom
Jul 18, 2019 Gmax Biopharm LLC. is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and Bibody development, to address …See details»
Gmax Biopharm - Overview, News & Similar companies
Nov 11, 2021 www.gmaxbiopharm.com. Revenue <$5 Million. Industry Business Services General Business Services . Recent News & Media. The World's First ETa-specific …See details»
Gmax Biopharm - VentureRadar
Gmax Biopharm LLC. is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and Bibody... ... Find out more ...See details»
Gmax Biopharm - Products, Competitors, Financials, Employees ...
Gmax Biopharm is a clinical-stage biopharmaceutical company that focuses on G-protein coupled receptors (GPCRs) therapeutic antibody and bibody development, to address the unmet …See details»
GPCRs|GPCR mAb discovery platform|Monoclonal Antibody …
Yuezhi Tao, Ph.D. Chief Operating Officier. Ph.D., Institute of Genetics, Chinese Academy of Sciences, China. Previously held leadership positions in the following institutions: …See details»
GMAX Zhengzhou Manufacturing Site Breaks Ground - BioSpace
HANGZHOU, China, Dec. 15, 2020 /PRNewswire/ -- Gmax Biopharm today holds ground-breaking ceremony for its Zhengzhou, China manufacturing site which is the production base …See details»
The World's First ETa-specific Monoclonal Antibody: Gmax …
Nov 14, 2022 Dr. Shuqian Jing, Founder and Chairman of Gmax Biopharm, said, "GMA131 is the first genuine ETa-specific monoclonal antibody developed by Gmax Biopharm.It …See details»
Gmax Biopharm LLC (鸿运华宁（杭州）生物医药有限公司) - 药物 …
了解Gmax Biopharm LLC (鸿运华宁（杭州）生物医药有限公司)公司的药物管线，治疗领域，技术平台，以及它的9项临床试验, 408篇新闻和3篇文献，疾病领域:内分泌与代谢疾病，肿瘤，免 …See details»
Research programme: monoclonal antibody therapeutics - Gmax …
If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to …See details»
Gmax's GMA106, second generation obesity/T2DM/NASH
HANGZHOU, China, Nov. 11, 2021 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA106 was given to human subjects in a phase ...See details»
GMAX Biopharm International raises USD 78M funding
The latest transaction, on March 5, attracted a slew of prominent investors including Chinese clinical contract research organization (CRO) Tigermed, Parkland Medtech Limited, Cowin …See details»
GMAX Biopharm gives first does of anti-body drug treating PAH in …
HANGZHOU, China, Oct. 26, 2020 /PRNewswire/ — Gmax Biopharm today announces that the first dose of GMA301 was given to the patient in its phase 1B trial to investigate the drug …See details»
GMAX Biopharm gives first does of anti-body drug treating PAH in …
HANGZHOU, China, Oct. 26, 2020 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA301 was given to the patient in its phase 1B trial to investigate the drug …See details»
GPCRs|GPCR mAb discovery platform|Monoclonal Antibody …
Gmax has built up a proprietary platform to overcome the obstacles in Ab generation targeting GPCRs. By leveraging the platform, Gmax has successfully generated a series of functional …See details»
Gmax’s GMA106, second generation obesity/T2DM/NASH mAb
HANGZHOU, China, Nov. 11, 2021 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA106 was given to human subjects in a phase 1 study to investigate the …See details»